922717-97-3
Chemical Structure
Rifaquizinone
Synonym(s): CBR-2092; TNP-2092
- CAS No.: 922717-97-3
- Formula:C65H81FN6O15
- Molecular Weight:1205.37
InChIKey: OPZFMLLAJBIKAN-KYGXCNJYSA-N
SMILES: CN(C1CCN(CC1)/N=C/C2=C3C(O)=C4C(C5=C(O[C@@](C5=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(C(N3)=O)/C)C)O)C)O)C)OC(C)=O)C)OC)C)C(C)=C4O)=C2O)C6([C@@]7([H])CN(C8=C(C9=C(C%10CC%10)C=C(C(N9C=C8F)=O)C(O)=O)C)CC7)CC6
Biological Activity: Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rifaquizinone | Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. [Content Brief]
- [2]. Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. [Content Brief]
Keywords
